You are here

  • Home
  • Archive
  • Volume 11, Issue 6
  • PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1

Article metrics

Article menu

This article has a correction. Please see:

Immunotherapy biomarkers
Original research
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis

 

Online download statistics by month:

Online download statistics by month: June 2023 to September 2025

AbstractFullPdf
Jun 2023628642157
Jul 202332432655
Aug 202321121224
Sep 202310610620
Oct 202312512933
Nov 202315015035
Dec 202310610766
Jan 202414014197
Feb 202411811973
Mar 2024123123224
Apr 2024909080
May 202411111587
Jun 2024909155
Jul 202410311278
Aug 2024697752
Sep 20245858835
Oct 202410910974
Nov 202414014271
Dec 202417517894
Jan 202510110263
Feb 202518418467
Mar 202511811873
Apr 202511711781
May 202510810885
Jun 2025646439
Jul 2025220
Sep 2025110
Total367137232618